The Norwegian preeclampsia family cohort study: a new resource for investigating genetic aspects and heritability of preeclampsia and related phenotypes by Linda Tømmerdal Roten et al.
RESEARCH ARTICLE Open Access
The Norwegian preeclampsia family cohort
study: a new resource for investigating
genetic aspects and heritability of
preeclampsia and related phenotypes
Linda Tømmerdal Roten1,2*, Liv Cecilie Vestrheim Thomsen3,4, Astrid Solberg Gundersen5,6,
Mona Høysæter Fenstad6,7, Maria Lisa Odland6, Kristin Melheim Strand1, Per Solberg8, Christian Tappert9,
Elisabeth Araya9, Gunhild Bærheim10, Ingvill Lyslo10, Kjersti Tollaksen10, Line Bjørge3,4 and Rigmor Austgulen6
Abstract
Background: Preeclampsia is a major pregnancy complication without curative treatment available. A Norwegian
Preeclampsia Family Cohort was established to provide a new resource for genetic and molecular studies aiming to
improve the understanding of the complex pathophysiology of preeclampsia.
Methods: Participants were recruited from five Norwegian hospitals after diagnoses of preeclampsia registered
in the Medical birth registry of Norway were verified according to the study’s inclusion criteria. Detailed obstetric
information and information on personal and family disease history focusing on cardiovascular health was collected.
At attendance anthropometric measurements were registered and blood samples were drawn. The software package
SPSS 19.0 for Windows was used to compute descriptive statistics such as mean and SD. P-values were computed
based on t-test statistics for normally distributed variables. Nonparametrical methods (chi square) were used for
categorical variables.
Results: A cohort consisting of 496 participants (355 females and 141 males) representing 137 families with increased
occurrence of preeclampsia has been established, and blood samples are available for 477 participants. Descriptive
analyses showed that about 60 % of the index women’s pregnancies with birth data registered were preeclamptic
according to modern diagnosis criteria. We also found that about 41 % of the index women experienced more than
one preeclamptic pregnancy. In addition, the descriptive analyses confirmed that preeclamptic pregnancies are more
often accompanied with delivery complications.
Conclusion: The data and biological samples collected in this Norwegian Preeclampsia Family Cohort will provide an
important basis for future research. Identification of preeclampsia susceptibility genes and new biomarkers may contribute
to more efficient strategies to identify mothers “at risk” and contribute to development of novel preventative therapies.
Keywords: Preeclampsia, Family-based cohort, Genetic predisposition, Pregnancy
* Correspondence: linda.tommerdal@ntnu.no
1Department of Laboratory Medicine, Children’s and Women’s Health, the
Norwegian University of Science and Technology (NTNU), 7491 Trondheim,
Norway
2Central Norway Regional Health Authority, 7501 Stjørdal, Norway
Full list of author information is available at the end of the article
© 2015 Roten et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Roten et al. BMC Pregnancy and Childbirth  (2015) 15:319 
DOI 10.1186/s12884-015-0754-2
Background
Preeclampsia is a serious complication specific to human
pregnancy affecting 3–5 % of all pregnant women in
Western countries [1]. Although the condition has been
documented already in ancient civilisations and has been
subject to extensive research, preeclampsia is still a
major cause of maternal and fetal morbidity and mortality
worldwide. The course of the disease is unpredictable and
it may rapidly progress to potentially life-threatening
seizures and organ failure. There is no curative treatment,
and delivery of the fetus and the placenta is the only way
to alleviate severe symptoms, irrespective of gestational
age. Aspirin is used as preventive medication in high-risk
pregnancies. However, the reduced incidence of pre-
eclampsia is only about 10 % [2]. In addition, the benefits
for women at moderate risk of preeclampsia are not as
clear. In order to develop effective preventive strategies
and diagnostic tests and markers for preeclampsia, we
need to increase our understanding of the complex patho-
physiology of this disease.
The exact pathophysiological mechanisms of preeclamp-
sia are not fully understood, however a model with two
main stages including both placental and maternal factors
has become widely accepted [3–5]. This conventional
model proposes that abnormal development of the pla-
centa results in reduced placental perfusion (stage 1) and
release of placental factors into the maternal circulation
leading to the clinical maternal manifestations of pre-
eclampsia (stage 2). There is now a growing realization that
preeclampsia may be classified as a syndrome and that
there may be several different preeclampsia phenotypes
(such as mild, severe, early onset, late onset, maternal, pla-
cental, recurrent). It has been suggested that different phe-
notypes may be distinguished by both clinical presentation
and by distinct biomarkers. Defining different preeclampsia
phenotypes by clinical and biochemical criteria in molecu-
lar studies may in the future lead to more specific thera-
peutic approaches [6].
Family-based studies have been the cornerstone of
identification and quantification of familial risk and her-
itability of human diseases, aiming to evaluate whether
familial clustering among cases is greater than expected.
Epidemiological studies have shown familial clustering
of preeclampsia implying a genetic component of the
disease [7–14]. Family studies have underpinned the im-
portant role of maternal genes in the development of
preeclampsia. Genome-wide linkage analyses have un-
covered evidence for several maternal susceptibility loci
in different populations [15–19]. Genetic factors are
found to be responsible for approximately 50 % of the
disease liability [18, 20]. By identification of genetic
factors conferring susceptibility to preeclampsia one may
contribute to elucidating the complex pathophysiology.
Increased knowledge of the role played by genetic
factors is also expected to increase our understanding of
environmental contributions [21]. The establishment of
the present cohort was inspired by the promising results
from genome-wide scans in preeclampsia families from
Iceland and Australia/New Zealand published in 1999
[15] and 2000 [18], respectively.
We aimed to establish a cohort of Norwegian families
with an increased occurrence of preeclampsia in order
to study the complex genetic architecture of this major
pregnancy specific syndrome. The planning was inde-
pendent of any specific genetic hypotheses. Our primary




Recordings in the Medical birth registry of Norway
(MBRN) from 1967 to 2005 was the basic data set used
to identify the potential index women to be invited to
the study. In Norway a notification form is sent to the
MBRN for all births by the midwife/doctor. This notifi-
cation includes information about biographical data of
the child’s parents, maternal health conditions before
and during pregnancy, complications during pregnancy
or at birth and the newborn’s health condition. For the
present study cohort we were interested in identifying
women with a familial predisposition for preeclampsia.
Familial predisposition was predefined as preeclamptic
women with a first degree relative (mother, daughter or
sister) also registered with preeclampsia in MBRN. Thus,
a preeclampsia family in our cohort would have at least
two affected women (potential index women). Mother-
daughter and sister-sister index pairs were identified by
linking MBRN data with The National Population Regis-
ter. Furthermore, the list of potential index women was
restricted to only include pairs of preeclamptic women
who had delivered at the hospitals involved in the study.
Medical records of the identified potential index women
(n = 1003) were reviewed by medical doctors at the delivery
wards involved in the study in order to assure recruitment
of women with a valid preeclampsia diagnosis according to
the diagnosis criteria set by The Norwegian Society of
Gynecology and Obstetrics (NGF) (Table 1). Departments
of Obstetrics and Gynaecology at the following hospitals
were involved in the study: St. Olavs University Hospital,
Haukeland University Hospital, Stavanger University Hos-
pital, Levanger Hospital, Namsos Hospital (Fig. 1). Lists of
women with confirmed valid diagnoses (i.e. index women)
(n = 634) and non-valid diagnoses (n = 369) were returned
from the departments of Obstetrics and Gynaecology to
MBRN. At MBRN the lists were edited by exclusion of
women without a valid preeclampsia diagnosis. Further-
more the sister/mother/daughter of these women was also
excluded. Women being dead or where contact
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information was missing were removed from the lists.
Thus, only alive mother-daughter or sister-sister pairs
where both women had a valid preeclampsia diagnosis
were invited to attend the study. The final number of index
women fulfilling our inclusion criteria was 426 of 634
(67.2 %) [22]. Inclusion criteria are summarized in Table 1.
Recruitment of participants
The personal identification number, name, address and
telephone number to all the 426 index women was for-
warded from MBRN to the hospitals involved in the
study. In order to motivate potential participants to
attend the study we aimed to attract attention to our
study by appearance in both national and local media
(newspapers, radio and television) prior to posting invi-
tation letters. From February 2009 to May 2011 the 426
index women were contacted from the involved delivery
departments. As paternal genetic factors appear to con-
tribute to preeclampsia susceptibility [23, 24] the invited
index women were encouraged to recruit their male
partner(s) fathering their pregnancies. Index women
agreeing to participate were also encouraged to recruit
other female and male family members. Index women
who had delivered at St. Olavs Hospital in Trondheim
were the first to be recruited to the study. The postal
invitations from St. Olavs Hospital included the invita-
tion letter, informed consent form, information to family
members, contact information and a questionnaire. Due
to the responses we got from the women recruited from
St. Olavs Hospital the procedure of posting invitations
from the other involved delivery wards were organized
differently. A post card notifying women that they were
going to be invited to the study and information regard-
ing local media appearance were sent first. One week
later the second postal item containing the invitation let-
ter, informed consent form, information to family mem-
bers, contact information and information about what to
do if they agreed to attend was sent. Women giving their
consent subsequently received the questionnaire. Non-
responders were either sent a postal reminder or were
contacted by phone.
A flow chart summarizing the process of identification,
validation of diagnoses and inclusion/participation is
shown in Fig. 1.
Data collection
All participants were invited to fill in a questionnaire, get
their height, weight and waist circumference measured
and donate blood samples. The questionnaire was accom-
plished in collaboration with a medical doctor. In addition,
obstetric information was collected from medical records
for index women who received postal invitation.
Questionnaire
A questionnaire was designed by researchers and medical
doctors in the project team establishing this Norwegian
Preeclampsia Family Cohort Study. The questionnaire
covers the following main topics: biographic information,
relevant information regarding pregnancies, self-reported
personal somatic health and diseases such as diabetes,
coronary heart disease, stroke and asthma, family and
family in-law health/disease history. Detailed obstetric in-
formation was collected from all female participants. A
summary of the type of data collected is shown in Table 2.
Biospecimens
Blood samples for analysis at different levels in the bio-
logical process of converting DNA to intermediate RNA
and executive proteins were collected. Three different
peripheral blood samples were collected from all partici-
pants; 1) EDTA whole blood sample (Puls-Norge), 2)
Tempus™ Blood RNA Tube (Applied Biosystems) sample
and 3) Serum Separating Tube (SST) (Puls-Norge) sam-
ple (Table 2). Buffy coat and plasma were extracted from
the EDTA blood sample and divided into aliquots. Ex-
traction of DNA from the buffy coats is accomplished,
and DNA is available for genetic studies. Serum was ex-
tracted from the SST samples and divided into aliquots,
whereas the Tempus™ Blood RNA Tubes containing a
RNA-stabilization reagent are stored until extraction of
RNA. All aliquots have been co-localized and are stored
at HUNT biobank (http://www.ntnu.edu/hunt/hunt-
biobank) in Levanger at −80 °C.
Linkage to routine data sources
The current cohort has a potential for follow-up studies.
However, only passive follow-up studies by linkage of
data from The Preeclampsia Family Cohort Study with
data from local, regional and national end-point registers
Table 1 Study inclusion criteria
Inclusion to: Criteria
A: Blood pressure
≥140/90 > 20 weeks
gestation
B: Proteinuria ≥0.3





≥ first degree relative
registered with
preeclampsia in MBRN
≥ first degree relative
with valid preeclampsia
diagnosis
Examination of medical hospital
record prior to invitation
x x x
Invitation to attend the study x x x x x
Criteria A, B and C together constitute the NGF diagnosis criteria for preeclampsia
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and routine data sources has been planned. Relevant regis-
ters for follow-up studies in the presented cohort are
MBRN, Cause of Death Register and local/regional hos-
pital disease registers e.g. on myocardial infarction and
stroke. Linkage to health registers is possible through the
unique Norwegian 11-digit personal identification number
after approval from the Regional Committee for Medical
and Health Research Ethics.
Statistical analyses
We compared maternal age at birth, placenta weight,
birth weight in preeclamptic pregnancies versus non-
Fig. 1 Flow chart summarizing the process of identification, validation of diagnoses and inclusion/participation
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preeclamptic pregnancies for the index women by using
independent sample t-test (two tailed) (significance level
0.01). Pearson chi square analysis in a 2 × 2 contingency
table was performed when comparing number of cesarean
sections, number of induced vaginal pregnancies with the
number of non-induced vaginal deliveries, the number
of acute with the number of planned cesarean sections
and the number of male with the number of female neo-
nates in preeclamptic pregnancies versus non-preeclamptic
pregnancies among the index women (significance level
0.05). All statistical analyses were performed in IBM SPSS
Statistics 19.
Power in genetic studies based on The Preeclampsia Family
Cohort Study
In general, the power to detect the effect of genes
depends on the effect size, the allele frequency and the
sample size. The ability to detect the genes (genetic
susceptibility variants) increases when sample size and
effect size increase. However, the choice of study design
and research strategy is still crucial for the chances of a
successful outcome in a genetic study. Figure 2 (adopted
from [25, 26]) shows the relationship between effect size
and allele frequency. Figure 3 (adopted from [27]) shows
what genetic variants that may be detected with three
primary strategies (genome-wide linkage, targeted se-
quencing and genome-wide association). Genome-wide
linkage analyses can only be performed in cohorts/
collections of biologically related individuals and are
preferred when searching for rare variants (allele fre-
quency <0.3 %) expected to have large effect size (odds
ratio (OR) > 5). Whereas, genome-wide association studies
(GWAS) in case-control or cohort studies, are better
suited to identify common variants (allele frequency >5 %)
of modest effect size (OR < 2).
The presented cohort is family-based and well suited
for genome-wide linkage analysis. Other research strat-
egies such as targeted resequencing and family-based as-
sociation analyses are also possible. The present cohort
consists of several nuclear families, and genetic studies
of these are likely to represent a more homogeneous and
limited set of causative genes and pathways. In addition,
we have performed thorough phenotyping of the cohort
[28]. These features are likely to enhance statistical power
for gene discovery in our cohort. Furthermore, significant
heritability estimates in the cohort support that there is an
increased susceptibility of preeclampsia [28]. High herit-
ability implying a strong correlation between phenotype
and genotype makes it easier to detect loci with an effect
on the trait. However, further research is needed as herit-
ability does not provide information about the genetic
architecture.
Ethical approval
The establishment of the Norwegian Preeclampsia Family
Cohort Study was approved by the Regional Committee
Table 2 Overview of data collected from participants
1. Questionnaire
a.Maternal characteristics Age at attendance, exposed for preeclampsia, parity, smoking habits and
medication during pregnancy
b.Paternal characteristics Age at attendance, exposed for preeclampsia, fathered a preeclamptic pregnancy
c.Pregnancy and birth characteristics Due date, date of birth, preeclampsia, gestational hypertension, gestational
diabetes, eclampsia, HELLP, mode of delivery (vaginal or cesarean section),
labor onset (spontaneous or induction), placental weight, experienced abortions
d.Offspring characteristics Sex, birth weight, twin or multiple
e.Self-reported personal disease history focusing on
preeclampsia, diabetes and cardiovascular disease
Time of onset of disease, duration of disease
f.Self-reported family disease history focusing on
preeclampsia, diabetes and cardiovascular disease




3. Biological samples (blood)
a.EDTA – 1 × 10 ml Buffy coat for DNA analyses (genetic and epigenetic), plasma for
protein/metabolites/nutrients analyses
b.Serum Separating Tube (SST) – 1 × 10 ml Serum for protein/metabolites/nutrients analyses
c.Tempus Blood RNA tubes – 1 × 9 ml (6 ml RNA stabilizing fluid) Whole blood for RNA analyses (gene expression and qualitative analyses)
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Fig. 2 Relationship between effect size and allele frequency (adopted from [25, 26]). Extremely rare genetic variants with large effect sizes (upper
left, strong red color) are often identified in family-based genome-wide linkage analyses. Common genetic variants with small effect sizes (lower
right, strong green color) have been identified in traditional GWAS (including only common variants). Rare variants with small effects (lower left) are
difficult to identify. Whereas common genetic variants with large effects (upper right) have been identified using both linkage analysis and GWAS,
however these are highly unusual for common diseases
Fig. 3 Primary research strategies for identification of genetic variants across the allele frequency spectrum (adopted from [27]). Genome-wide
linkage studies are well suited to identification of genetic variants with allele frequencies below 0.3 % with large effect sizes (OR > 5). Targeted
resequencing often leads to identification of genetic variants with allele frequencies between 0.3 and 5 % with moderate effect sizes (2 < OR < 5),
but may also be used to identify rare variants with large effects and common variants with modest effects. Traditional GWAS is suited to identification
of common genetic variants with modest effect sizes (OR < 2)
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for Medical Research Ethics Mid-Norway, the National
Data Inspectorate and The Directorate of Health and
Social Welfare in Norway. All participants gave their in-
formed consent when attending the study.
Data access
The Preeclampsia Family Cohort Study data and biological
material are held by the research team at Haukeland
University Hospital, Bergen Health Authority and the
Department of Cancer Research and Molecular Medicine,
Faculty of Medicine, Norwegian University of Science and
Technology (NTNU). Access to the data is not freely avail-
able. However, The Preeclampsia Family Cohort Study data
and biological material have the potential to be subject
of many internally and externally collaborations. Poten-
tial collaborators should discuss ideas informally with
the person in charge of the cohort study, Line Bjørge
(Line.Bjorge@uib.no). Specific proposals for collabora-
tive ideas are welcome and when relevant approvals are
consented research projects should be conducted in
collaboration with appropriate members of The Pre-
eclampsia Family Cohort Study team. The Preeclampsia
Family Cohort Study is completely researcher-driven
and funded from several research grants, thus all poten-
tial collaborators must cover all costs related to poten-
tial analyses.
Results
Sample size and response fractions
A participant is a person who has given a written in-
formed consent, donated blood samples and/or been
interviewed and who’s questionnaire has been filled in.
The total participation rate for all eligible index women
was 51.6 % (220/426). Of the eligible mother-daughter
pairs 42.2 % (18/42) attended the study, whereas 38.8 %
(64/165) of the eligible sister-sister pairs attended (Table 3).
In total there are 496 participants in the Preeclampsia
Family Cohort Study, 355 female and 141 male partici-
pants, whereas blood samples are available for 477 partici-
pants. Of the participating index women 37.3 % (82/220)
recruited their husbands/partners to attend the study.
Other male relatives also attended, and 15 of them re-
ported that they had fathered a preeclamptic pregnancy.
Of the male participants fathering preeclamptic pregnan-
cies 23 also have an offspring participating in the study,
enabling analyses of relationships between mother, father
and child.
Characteristics of participants
Preeclampsia is a heterogeneous condition and defining
different preeclampsia phenotypes by clinical criteria is
likely to improve the chances of finding molecular fac-
tors distinguishing these phenotypes. A comprehensive
characterization of phenotypic subgroups in the total
cohort has been carried out and is presented in a separ-
ate publication recently published. In this publication
heritability of different preeclampsia phenotypes and
also related conditions such as atherothrombotic car-
diovascular diseases (aCVD) has been estimated in the
present cohort [28].
Descriptive statistics of index women
Descriptive statistics of index women and their pregnan-
cies are presented in Table 4. About 60 % (326/547) of
the index women’s pregnancies with birth data registered
was preeclamptic according to NGF diagnosis criteria
(Table 4). Among the index women 40.9 % (90/220)
experienced more than one preeclamptic pregnancy
(recurrent preeclampsia). It is generally known that
preeclamptic pregnancies are more often accompanied
with delivery complications. As expected the number
of cesarean sections compared with the number of va-
ginal deliveries was found to be significantly higher in
preeclamptic pregnancies versus non-preeclamptic preg-
nancies (p = 3.2 × 10−5) in our cohort (Table 4). The num-
ber of induced vaginal deliveries was also found to be
significantly higher in preeclamptic pregnancies compared
with the non-preeclamptic pregnancies (p = 3.2 × 10−27)
(Table 4). Furthermore, acute cesarean sections are signifi-
cantly more frequent than planned cesarean sections in
preeclamptic pregnancies compared with non-preeclamtic
pregnancies (p = 5.6 × 10−4). A significance level of 0.05
was set when performing the Pearson chi square tests.
Placenta weight and birth weight was found to be sig-
nificantly lower in preeclamptic pregnancies compared
with non-preeclamptic pregnancies (p = 0.9 × 10−5 and
Table 3 Number of eligible and participating index women and families in the Preeclampsia Family Cohort Study
Invited Attending Participation rate (%)
Index women 426 220 51.6
Mother-daughter pairs 42 18 42.9
Sister-sister pairs 165 64 38.8
Three sisters 5 1 20.0
Familiy with at least two index women participating 209 81 38.8
Familiy represented in the cohort by one or more participantsa 209 137 65.6
aIn 56 families only one of the eligible index women participated
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p = 1.9 × 10−15 respectively) as expected (Table 4) at a
significance level of 0.01.
Distribution of non-gestational diseases related to
preeclampsia in index women
As shown in Table 2, self-reported information on non-
gestational disease phenotypes related to development of
preeclampsia was collected. Definition of and proportion
of disease phenotypes in the total cohort is presented in
a paper by Thomsen et al. [28]. Whereas, the proportion
of diabetes, pulmonary disease, autoimmune (including
systemic lupus erythematosus), aCVD, kidney disease,
chronic hypertension, hypercholesterolemia, myocardial
infarction/angina, stroke and thrombosis in the index
women is shown in Table 5. As in the total cohort,
aCVD (30.7 %) and chronic hypertension (25.1 %) were
the most prevalent disease phenotypes in index women.
Discussion
We have successfully established a unique family-based
cohort consisting of Norwegian families with increased
occurrence of preeclampsia. All families were identified
with at least two first degree related women with a valid
preeclampsia diagnosis according to modern diagnosis
criteria. One of the main strengths of the Preeclampsia
Family Cohort Study is that it holds both biological
material and detailed health-related information, and
also the ability to collect complemental information
from local, regional or national routine data sources.
Thus, the established cohort represents a new resource
Table 4 Selected clinical characteristics of index women and their pregnancies
Pregnancies among index women Preeclamptic pregnancies among index women Non-preeclamptic pregnancies
among index women
(Pregnancies with birth data n = 547)
(Live birth pregnancies n = 544)
(n = 326) (n = 214)
Age at delivery no. (mean ± standard deviation)
1 24.5 ± 4.9 (n = 214) 24.8 ± 5 (n = 181) 23.1 ± 4.0 (n = 32)
2 27.7 ± 4.5 (n = 194) 28.2 ± 4.4 (n = 89) 27.3 ± 4.7 (n = 103)
3 30.6 ± 4.6 (n = 95) 31.1 ± 4.9 (n = 44) 30.2 ± 4.4 (n = 51)
4 31.9 ± 3.2 (n = 27) 31.5 ± 4.1 (n = 10) 32.1 ± 2.6 (n = 17)
5 33.2 ± 4.2 (n = 9) 31.5 ± 6.4 (n = 2) 33.7 ± 3.9 (n = 7)
Multiple pregnancy n = 7 n = 4 n = 3
Mode of delivery
Vaginala,b n = 396 n = 215 n = 178
Inducedb n = 196 n = 160 n = 35
Cesarean sectiona n = 136 n = 102 n = 34
Plannedc n = 37 n = 20 n = 17
Acutec n = 99 n = 82 n = 17
Placenta weightd 591 ± 164 (264 valid, 283 missing) 560 ± 166 (173 valid, 155 missing) 653 ± 138 (89 valid, 125 missing)
Birth weighte 3189 ± 843 (528 valid, 19 missing) 2981 ± 874 (321 valid, 7 missing) 3526 ± 645 (204 valid, 10 missing)
Neonate sex
Male n = 261 n = 152 n = 106
Female n = 288 n = 180 n = 108
Experienced abortions
Spontaneous n = 89
Induced n = 43
aComparing the number of vaginal deliveries with the number of cesarean sections in preeclamptic pregnancies versus non-preeclamtic pregnancies there is a
significant difference using Pearson’s chi square analysis in a 2 × 2 contingency table. The number of cesarean sections was significantly higher in preeclamptic
pregnancies (p = 3.2 × 10−5)
bComparing the number of induced vaginal deliveries with the number of non-induced vagnial deliveries in preeclamptic pregnancies versus non-preeclamtic
pregnancies there is a significant difference using Pearson’s chi square analysis in a 2 × 2 contingency table. The number of induced vaginal deliveries was
significantly higher in preeclamptic pregnancies (p = 3.2 × 10−27)
cComparing the number of acute cesarean sections with the number of planned cesarean sections in preeclamptic pregnancies versus non-preeclamtic pregnancies
there is a significant difference using Pearson’s chi square analysis in a 2 × 2 contingency table. The number of acute cesarean sections was significantly higher in
preeclamptic pregnancies (p = 5.6 × 10−4)
dThe placenta weight in preeclamptic pregnancies was significantly lower compared with non-preeclamptic pregnancies using t-test statistics (p = 0.9 × 10−5)
eThe birth weight of neonates born from preeclamptic pregnancies was significantly lower compared with non-preeclamptic pregnancies using t-test
statistics (p = 1.9 × 10−15)
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for researching genetic and molecular aspects of pre-
eclampsia, and also provides an important basis for
translational research.
The descriptive statistics of the index women’s preg-
nancies presented in this paper did not show any unex-
pected results. We found that women experiencing
preeclamptic pregnancies are significantly more affected
by labor and delivery complications. Another observa-
tion was that many of the index women (40.9 %) have
experienced more than one preeclamptic pregnancy.
The most likely explanation for lower placenta and birth
weight in preeclamptic compared with non-preeclamptic
pregnancies is that these pregnancies usually are shorter.
It has been suggested that rare genetic variants may
have a greater impact on disease development. Rare gen-
etic variants with large effects on specific traits are likely
to better help us understand the underlying biology of
health and disease than common variants conferring
moderate effect on complex traits [29–31]. Thus, atten-
tion to rare genetic variants has increased and led to a
renaissance for family-based studies in the post-GWAS
era since these variants are easier to identify with family-
based designs. In addition, new high throughput sequen-
cing technology has revolutionized the field of molecular
genetic research by raising new opportunities to dissect
common complex diseases such as preeclampsia.
Family-based cohorts are difficult and challenging to
establish. In the presented cohort the total participation
rate for all eligible index women was 51.6 % (220/426).
The low participation rate is a limitation of the study as
sample size affects the power to detect the effect of
genes. Low participation rate may also lead to selection
bias. However, in general family-based designs have sev-
eral advantages compared to population-based designs
in genetic studies [32]. Data on sib pairs, nuclear families
and extended pedigrees can be used to make inferences
in all of the major areas of genetics i.e. estimation of her-
itability of a trait, localize quantitative trait loci (QTLs) via
linkage information and use association information to
fine-map and identify QTLs (see Table 6) [32].
An advantage of family-based designs is that they are
robust against population substructure [33]. Significant
findings always imply both linkage and association [34],
and one therefore avoids false positives (Type I errors)
that often arise when association is present but linkage
is not. Family-based designs also have substantial bene-
fits in terms of accounting for multiple-hypothesis test-
ing, especially when hundreds of thousands of genetic
markers are tested simultaneously, because they contain
both within- and between-family information [35]. In
addition, family data and material that have already been
collected for genome-wide linkage studies may be
recycled for association analyses, also in population-
based studies [36, 37].
In family-based designs one has the ability to make
use of familial correlations to increase power using strat-
egies such as the “extreme discordant and concordant”
design, obtain information on genetic haplotypes thus
avoiding haplotype estimation/prediction and provide
parent of origin information. This means that studies of
families may have superior power to detect clinically
relevant genetic variants compared to population-based
cohort studies. Family-based designs focusing on identi-
fying gene loci associated with important quantitative
traits are also likely to complement population-based co-
hort studies and other studies with the ability to focus
on gene-environment interactions. It has been suggested
that family samples can provide substantially greater
power for rare variant association studies because there
is a potential for observing many copies of a rare genetic
variant associated with a disease or trait. This has been
called the “jackpot” effect [37].
In the present cohort study we have the ability to carry
out the transmission-disequilibrium test (TDT), which is
a simultaneous test for linkage and association. The clas-
sical TDT is a completely non-parametric test compar-
ing transmitted with non-transmitted parental alleles. A
Table 5 Distribution of non-gestational diseases related to
development of preeclampsia in index women
Disease phenotype Proportion (%)
Diabetes mellitus type 1 1/214 (0.5)
Diabetes mellitus type 2 9/213 (4)
Gestational diabetes 15/214 (7.0)
Kidney disease 3/215 (1.4)
Pulmonary disease 29/215 (13.5)
Autoimmune disease 26/214 (12.1)
aCVD 66/215 (30.7)
Chronic hypertension 54/215 (25.1)
Hypercholesterolemia 20/215 (9.3)
Myocardial infarction/Angina 3/215 (1.4)
Stroke 0/214 (0)
Thrombosis 7/215 (3.3)
aCVD atherothrombotic cardiovascular disease
Table 6 Major types of sampling designs in human genetics
and the types of genetic inferences that can be made (modified
from [32])
Sampling design Possible inferences
Heritability Linkage Association
Unrelated individuals – – +
Triads (parents, one offspring) – + +
Sibling pairs + + +
Nuclear families + + +
Extended pedigrees + + +
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major advantage of this test is the robustness to poten-
tial misspecification of any of the features of the disease
model or trait/phenotype distribution since the validity
of the test does not require proper specification of the
mode of inheritance (disease model) or assumptions
about the distribution of the disease in the population.
Preeclampsia is a complex and heterogeneous syndrome
that is not only a maternal disease influenced by maternal
genetic risk factors. Due to the placental origin of pre-
eclampsia it is likely that fetal and/or paternal genetic fac-
tors play a central role in the pathogenesis. Evidence is
supporting that paternal and/or fetal genetic factors might
contribute to the risk of preeclampsia [23, 24, 38]. It has
been shown that men born from preeclamptic pregnancies
are at a higher risk of fathering a preeclamptic pregnancy
[23], and men who have fathered a preeclamptic pregnancy
have an increased risk of fathering another preeclamptic
pregnancy with a different partner [24]. Thus, it is import-
ant to include the father and the offspring in genetic stud-
ies of preeclampsia. This may be possible in studies based
on the Preeclampsia Family Cohort Study.
Family-based study designs allow for sub-designs, such as
case-parent triads, that open the possibility of detecting ma-
ternal, paternal and fetal genes and also their interactions.
Gene-environment interactions may also be detected in
case-parent triads if stratified by environmental exposure.
The majority of genetic studies of preeclampsia have fo-
cused on the maternal genetic contribution. This is also the
case for genome-wide family linkage analyses. However, re-
cently it has been shown that fetal susceptibility loci also
may be detected by linkage analysis [39]. The repeated
pregnancy design where the maternal genome is unchanged
and the fetal genotype changes is another sub-design to
examine maternal and fetal genotype and interaction with
environmental exposures in family-based studies.
The fact that all families in the Norwegian Preeclampsia
Family Cohort Study are identified with two “true” pre-
eclamptic women, implying that there is a clear familial
aggregation of the disease, strengthens the potential to un-
cover genetic factors contributing to development of pre-
eclampsia. Significant heritability estimates in the cohort
also support that there is an increased susceptibility of
preeclampsia [28]. Relatively strict inclusion criteria were
used in the identification process for our cohort in order
to reduce phenotypic heterogeneity and improve power.
However, as a result sample size was reduced at the cost
of some statistical power.
Another weakness of cohorts with disease-based ascer-
tainment is that studies based on these cohorts are essen-
tially limited to the investigation of a single or only a small
spectrum of phenotypes. Although the main phenotype in
the present cohort is preeclampsia findings based on our
cohort are likely to be relevant to other major health issues
among women, such as cardiovascular disease (CVD). The
reason for this is the association between preeclampsia and
development of maternal CVD later in life which has been
well established through epidemiological research [40–46].
Pathological features such as endothelial dysfunction and
inflammation and also many common risk factors are
shared between these conditions [44, 45, 47–51]. Further-
more, recent empirical evidence supporting the hypothesis
that genetic risk factors underlying preeclampsia are shared
with CVD-related traits is now emerging [52–55]. A his-
tory of preeclampsia has also been associated with subse-
quent maternal health risks including adverse effects on
diabetes and cancers (reviewed in [40, 56]). In this regard,
the present cohort study holds a unique feature namely the
ability to link individual data with relevant and detailed
morbidity, mortality and other routine data sources. Thus,
follow-up studies may be carried out through linkage of
the presented cohort with local, regional or national rou-
tine data sources and potentially also through review of
medical hospital records.
A major weakness of cohorts including more than one
generation is that blood samples most often are drawn
independent of the onset of the disease/condition under
study. As in the presented cohort the blood samples
were not drawn when the women were pregnant. Thus,
the utility of blood samples in family-based cohorts to
study complex genetic diseases are somewhat limited to
studies of genetic predisposition and less valuable for
functional studies. However, studies in family-based co-
horts may generate novel hypotheses that can be tested
functionally in different human samples or in different
model systems.
Conclusions
The Norwegian Preeclampsia Family Cohort Study has re-
cently been completed and made available for research.
On-going genetic studies in the cohort remain to discover
what genomic regions are linked to preeclampsia in the
Norwegian families, and if these comply with previous
linkage studies in Icelandic, Australian/New Zealand,
Finnish and Dutch families. Furthermore, we aim to iden-
tify novel susceptibility genes, pathways and causal genetic
variants in order to help understanding the pathophysi-
ology of preeclampsia and also cardiovascular disease in
women. The presented cohort provides an important basis
for future genetic, molecular and epidemiological studies
of preeclampsia and associated traits.
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